FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Allan van Oosterom

Research Profile

Chemicals & Drugs

Concepts & Ideas

Disorders

Procedures

Anatomy

Erythrocytes

Co-author Network

Publications

TOP 3
Piotr Rutkowski; Martine Van Glabbeke; Cathryn J Rankin; Wlodzimierz Ruka; Brian P Rubin; Maria Debiec-Rychter; Alexander Lazar; Hans Gelderblom; Raf Sciot; Dolores Lopez-Terrada; Peter Hohenberger; Allan T van Oosterom; Scott M Schuetze
Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.
Eric Baudin; Jean P Droz; Luis Paz-Ares; Allan T van Oosterom; Martin Cullell-Young; Martin Schlumberger
Phase II study of plitidepsin 3-hour infusion every 2 weeks in patients with unresectable advanced medullary thyroid carcinoma.
Toon Maes; Hans Wildiers; Sam Heye; Wim Demey; Geert Maleux; Patrick Neven; Allan T van Oosterom; Robert Paridaens
Intra-hepatic Mitomycin C bolus infusion in the treatment of extensive liver metastases of breast cancer.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Allan van Oosterom (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2010: Piotr Rutkowski; Martine Van Glabbeke; Cathryn J Rankin; Wlodzimierz Ruka; Brian P Rubin; Maria Debiec-Rychter; Alexander Lazar; Hans Gelderblom; Raf Sciot; Dolores Lopez-Terrada; Peter Hohenberger; Allan T van Oosterom; Scott M Schuetze
Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(10):1772-9.
2010: Eric Baudin; Jean P Droz; Luis Paz-Ares; Allan T van Oosterom; Martin Cullell-Young; Martin Schlumberger
Phase II study of plitidepsin 3-hour infusion every 2 weeks in patients with unresectable advanced medullary thyroid carcinoma.
American journal of clinical oncology 2010;33(1):83-8.
2008: Toon Maes; Hans Wildiers; Sam Heye; Wim Demey; Geert Maleux; Patrick Neven; Allan T van Oosterom; Robert Paridaens
Intra-hepatic Mitomycin C bolus infusion in the treatment of extensive liver metastases of breast cancer.
Breast cancer research and treatment 2008;110(1):135-42.
2008: Patrick Schöffski; Herlinde Dumez; Pascal Wolter; Cristiana Stefan; Agnieszka Wozniak; Jose Jimeno; Allan T van Oosterom
Clinical impact of trabectedin (ecteinascidin-743) in advanced/metastatic soft tissue sarcoma.
Expert opinion on pharmacotherapy 2008;9(9):1609-18.
2008: Martina Baur; Allan T van Oosterom; Véronique Diéras; Michèle Tubiana-Hulin; R Charles Coombes; Thomas Hatschek; Michael Murawsky; May Klink-Alakl; Marcus Hudec; Christian Dittrich
A phase II trial of docetaxel (Taxotere) as second-line chemotherapy in patients with metastatic breast cancer.
Journal of cancer research and clinical oncology 2008;134(2):125-35.
2007: Jaap Verweij; Paolo G Casali; Dusan Kotasek; Axel Le Cesne; Peter Reichard; Ian R Judson; Rolf Issels; Allan T van Oosterom; Martine Van Glabbeke; Jean-Yves Blay
Imatinib does not induce cardiac left ventricular failure in gastrointestinal stromal tumours patients: analysis of EORTC-ISG-AGITG study 62005.
European journal of cancer (Oxford, England : 1990) 2007;43(6):974-8.
2007: Herlinde Dumez; Helen Gall; Renaud Capdeville; Catherine Dutreix; Allan T van Oosterom; Giuseppe Giaccone
A phase I and pharmacokinetic study of LAF389 administered to patients with advanced cancer.
Anti-cancer drugs 2007;18(2):219-25.
2007: Herlinde Dumez; Marc Martens; Johan Selleslach; Gunther Guetens; Gert de Boeck; Rita Aerts; Ernst A de Bruijn; Robert A A Maes; Allan T van Oosterom
Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothelium: results of a phase II and pharmacologic study.
Anti-cancer drugs 2007;18(2):211-8.
2006: George D Demetri; Allan T van Oosterom; Christopher R Garrett; Martin E Blackstein; Manisha H Shah; Jaap Verweij; Grant McArthur; Ian R Judson; Michael C Heinrich; Jeffrey A Morgan; Jayesh Desai; Christopher D Fletcher; Suzanne George; Carlo L Bello; Xin Huang; Charles M Baum; Paolo G Casali
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.
Lancet 2006;368(9544):1329-38.
2006: Hans Prenen; Herlinde Dumez; Cristiana Stefan; Ann Hoeben; Carine Wouters; Marie-Anne Van Lierde; Raf Sciot; Allan T van Oosterom; Marc Peeters; Marc Polus; Lionel DUCK; Thierry Gil; Patrick Schöffski
Imatinib for the treatment of patients with unresectable or metastatic malignant KIT-positive gastrointestinal stromal tumours: an open-label Belgian trial.
Acta gastro-enterologica Belgica 2006;69(4):367-71.
2006: Martine Van Glabbeke; Jaap Verweij; Paolo G Casali; R John Simes; Axel Le Cesne; Peter Reichardt; Rolf Issels; Ian R Judson; Allan T van Oosterom; Jean-Yves Blay
Predicting toxicities for patients with advanced gastrointestinal stromal tumours treated with imatinib: a study of the European Organisation for Research and Treatment of Cancer, the Italian Sarcoma Group, and the Australasian Gastro-Intestinal Trials Group (EORTC-ISG-AGITG).
European journal of cancer (Oxford, England : 1990) 2006;42(14):2277-85.
2006: Erin R Gardner; Herman Burger; Ron van Schaik; Allan T van Oosterom; Ernst A de Bruijn; Gunther Guetens; Hans Prenen; Floris A de Jong; Sharyn D Baker; Susan E Bates; William D Figg; Jaap Verweij; Alex Sparreboom; Kees Nooter
Association of enzyme and transporter genotypes with the pharmacokinetics of imatinib.
Clinical pharmacology and therapeutics 2006;80(2):192-201.
2006: Hans Prenen; Gunther Guetens; Gert de Boeck; Martin Highley; Allan T van Oosterom; Ernst A de Bruijn
Everolimus alters imatinib blood partition in favour of the erythrocyte.
The Journal of pharmacy and pharmacology 2006;58(8):1063-6.
2006: Maria Debiec-Rychter; Raf Sciot; Axel Le Cesne; Marcus Schlemmer; Peter Hohenberger; Allan T van Oosterom; Jean-Yves Blay; Serge Leyvraz; Michel Stul; Paolo G Casali; John Zalcberg; Jaap Verweij; Martine Van Glabbeke; Anne Hagemeijer; Ian Judson
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.
European journal of cancer (Oxford, England : 1990) 2006;42(8):1093-103.
2006: Ann Hoeben; Bart Landuyt; Gehan Botrus; Gert de Boeck; Gunther Guetens; Martin Highly; Allan T van Oosterom; Ernst A de Bruijn
Proteomics in cancer research: methods and application of array-based protein profiling technologies.
Analytica chimica acta 2006;564(1):19-33.
2006: Michael C Heinrich; Grant A McArthur; George D Demetri; Heikki Joensuu; Petri Bono; Richard Herrmann; Hal Hirte; Sara Cresta; D Bradley (Bradley) Koslin; Christopher L Corless; Stephan Dirnhofer; Allan T van Oosterom; Zariana Nikolova; Sasa Dimitrijevic; Jonathan A Fletcher
Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(7):1195-203.
2006: Gunther Guetens; Hans Prenen; Gert de Boeck; Martin Highley; Ivo De Wever; Allan T van Oosterom; Ernst A de Bruijn
Imatinib (Gleevec, Glivec) tumour tissue analysis by measurement of sediment and by liquid chromatography tandem mass spectrometry.
Journal of separation science 2006;29(3):453-9.
2006: G Huygh; Paul M J Clement; Herlinde Dumez; Patrick Schöffski; Hans Wildiers; Johan Selleslach; J M Jimeno; I De Wever; R Sciot; Lionel DUCK; Allan T van Oosterom
Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients.
Sarcoma 2006;2006():56282.
2006: Hans Prenen; Gunther Guetens; Gert de Boeck; Maria Debiec-Rychter; Paul Manley; Patrick Schoffski; Allan T van Oosterom; Ernst A de Bruijn
Cellular uptake of the tyrosine kinase inhibitors imatinib and AMN107 in gastrointestinal stromal tumor cell lines.
Pharmacology 2006;77(1):11-6.
2005: Sophie D Fosså; B Paluchowska; A Horwich; G Kaiser; P H M De Mulder; O Koriakine; Allan T van Oosterom; Linda de Prijck; Laurence Collette; Ronald de Wit
Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948).
British journal of cancer 2005;93(11):1209-14.
2005: Ronald Hoekstra; Herlinde Dumez; Ferry A L M Eskens; Ate van der Gaast; A S T Planting; Gerda de Heus; Kurt C Sizer; Christina Ravera; Sujata Vaidyanathan; Corazon D Bucana; Isaiah J Fidler; Allan T van Oosterom; Jaap Verweij
Phase I and pharmacologic study of PKI166, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(19 Pt 1):6908-15.
2005: Herlinde Dumez; Gunther Guetens; Gert de Boeck; Martin Highley; Ernst A de Bruijn; Allan T van Oosterom; Robert A A Maes
In vitro partition of irinotecan (CPT-11) in human volunteer blood: the influence of concentration, gender and smoking.
Anti-cancer drugs 2005;16(8):893-5.
2005: Herlinde Dumez; Gunther Guetens; Gert de Boeck; Martin Highley; Ernst A de Bruijn; Allan T van Oosterom; Robert A A Maes
In vitro partition of docetaxel and gemcitabine in human volunteer blood: the influence of concentration and gender.
Anti-cancer drugs 2005;16(8):885-91.
2005: Martine Van Glabbeke; Jaap Verweij; Paolo G Casali; Axel Le Cesne; Peter Hohenberger; ISABELLE RAY COQUARD; Marcus Schlemmer; Allan T van Oosterom; David Goldstein; Raf Sciot; Pancras Hogendoorn; Michelle Brown; Rossella Bertulli; Ian R Judson
Initial and late resistance to imatinib in advanced gastrointestinal stromal tumors are predicted by different prognostic factors: a European Organisation for Research and Treatment of Cancer-Italian Sarcoma Group-Australasian Gastrointestinal Trials Group study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(24):5795-804.
2005: Gunther Guetens; Hans Prenen; Gert de Boeck; Walter Van Dongen; Eddy L Esmans; filip Lemiere; Allan T van Oosterom; Patrick Schöffski; Ernst A de Bruijn
Sensitive and specific quantification of the anticancer agent ZD1839 (Gefitinib) in plasma by on-column focusing capillary liquid chromatography-tandem mass spectrometry.
Journal of chromatography. A 2005;1082(1):2-5.
2005: Patrick Pauwels; Maria Debiec-Rychter; Michel Stul; Ivo De Wever; Allan T van Oosterom; Raf Sciot
Changing phenotype of gastrointestinal stromal tumours under imatinib mesylate treatment: a potential diagnostic pitfall.
Histopathology 2005;47(1):41-7.
2005: Nina Aass; P H M De Mulder; Gerald H J Mickisch; Peter Mulders; Allan T van Oosterom; Hein van Poppel; Sophie D Fossa; Linda de Prijck; Richard J Sylvester
Randomized phase II/III trial of interferon Alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell Carcinoma: the European Organisation for Research and Treatment of Cancer Genito-Urinary Tract Cancer Group (EORTC 30951).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(18):4172-8.
2005: Otto Soepenberg; Herlinde Dumez; Jaap Verweij; Floris A de Jong; M J A de Jonge; José Thomas; Ferry A L M Eskens; Ron van Schaik; Johan Selleslach; Judith ter Steeg; Patricia Lefebvre; Sylvie Assadourian; Ger-Jan Sanderink; Alex Sparreboom; Allan T van Oosterom
Phase I pharmacokinetic, food effect, and pharmacogenetic study of oral irinotecan given as semisolid matrix capsules in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(4):1504-11.
2005: Otto Soepenberg; Herlinde Dumez; Jaap Verweij; Dorothee Semiond; Maja J A deJonge; Ferry A L M Eskens; Judith ter Steeg; Johan Selleslach; Sylvie Assadourian; Ger-Jan Sanderink; Alex Sparreboom; Allan T van Oosterom
Phase I and pharmacokinetic study of oral irinotecan given once daily for 5 days every 3 weeks in combination with capecitabine in patients with solid tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(4):889-98.
2004: Ann Hoeben; Bart Landuyt; Martin Highley; Hans Wildiers; Allan T van Oosterom; Ernst A de Bruijn
Vascular endothelial growth factor and angiogenesis.
Pharmacological reviews 2004;56(4):549-80.
2004: Bart Landuyt; Hans Prenen; Maria Debiec-Rychter; Raf Sciot; Ernst A de Bruijn; Allan T van Oosterom
Differential protein expression profile in gastrointestinal stromal tumors.
Amino acids 2004;27(3-4):335-7.
2004: Sophie D Fosså; Gerald H J Mickisch; P H M De Mulder; Simon Horenblas; Allan T van Oosterom; Hein van Poppel; Martin Fey; Jelle J Croles; Linda de Prijck; Martine Van Glabbeke
Interferon-alpha-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma.
Cancer 2004;101(3):533-40.
2004: M J A de Jonge; J P Droz; L Paz-Ares; Allan T van Oosterom; Ronald de Wit; P Chollet; B Baron; D Lacombe; K Mettinger; P Fumoleau
Phase II study on 9-nitrocamptothecin (RFS 2000) in patients with advanced or metastatic urothelial tract tumors.
Investigational new drugs 2004;22(3):329-33.
2004: Floris M Wachters; Harry J M Groen; Jan Gerard Maring; Jourik A Gietema; M Porro; H Dumez; E G E de Vries; Allan T van Oosterom
A phase I study with MAG-camptothecin intravenously administered weekly for 3 weeks in a 4-week cycle in adult patients with solid tumours.
British journal of cancer 2004;90(12):2261-7.
2004: Randal D'hondt; Robert Paridaens; Hans Wildiers; Karen Pauwelyn; Jose Thomas; Herlinde Dumez; Allan T van Oosterom
Safety and efficacy of weekly docetaxel in frail and/or elderly patients with metastatic breast cancer: a phase II study.
Anti-cancer drugs 2004;15(4):341-6.
2004: Maria Debiec-Rychter; Herlinde Dumez; Ian Judson; Bartosz Wasag; Jaap Verweij; M Brown; Sasa Dimitrijevic; Raf Sciot; Michel Stul; H Vranck; Michelle Scurr; Anne Hagemeijer; Martine Van Glabbeke; Allan T van Oosterom
Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group.
European journal of cancer (Oxford, England : 1990) 2004;40(5):689-95.
2004: Herlinde Dumez; Gunther Guetens; Gert de Boeck; Martin Highley; Robert A A Maes; Allan T van Oosterom; Ernst A de Bruijn
The relevance of therapeutic drug monitoring in plasma and erythrocytes in anti-cancer drug treatment.
Clinical chemistry and laboratory medicine : CCLM / FESCC 2004;42(11):1219-27.
2004: Mohamed Saad Ismail; Wim Wynendaele; Joeri L E Aerts; Robert Paridaens; Rabab Mohamed Gaafar; Nayera Shakankiry; Hussein M Khaled; Marie-Rose Christiaens; Hans Wildiers; Sherif Omar; Philippe Vandekerckhove; Allan T van Oosterom
Detection of micrometastatic disease and monitoring of perioperative tumor cell dissemination in primary operable breast cancer patients using real-time quantitative reverse transcription-PCR.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(1 Pt 1):196-201.
2004: Hans Wildiers; Bisan Ahmed; Gunther Guetens; Gert de Boeck; Ernst A de Bruijn; Willy Landuyt; Allan T van Oosterom
Combretastatin A-4 phosphate enhances CPT-11 activity independently of the administration sequence.
European journal of cancer (Oxford, England : 1990) 2004;40(2):284-90.
2003: Gunther Guetens; Gert de Boeck; Martin Highley; Herlinde Dumez; Allan T van Oosterom; Ernst A de Bruijn
Quantification of the anticancer agent STI-571 in erythrocytes and plasma by measurement of sediment technology and liquid chromatography-tandem mass spectrometry.
Journal of chromatography. A 2003;1020(1):27-34.
2003: Hans Wildiers; Bisan Ahmed; Gunther Guetens; Gert de Boeck; Ernst A de Bruijn; Willy Landuyt; Allan T van Oosterom
Unexpected interactions between nicotinamide and CPT-11 in a rhabdomyosarcoma tumor model.
Anticancer research 2003;23(5A):4055-9.
2003: M Saad Ismail; Wim Wynendaele; Joeri L E Aerts; Robert Paridaens; L Van Mellaert; Jozef Anne; Rabab Mohamed Gaafar; N Shakankiry; Hussein M Khaled; Marie-Rose Christiaens; S Omar; P Vandekerckhove; Allan T van Oosterom
Real-time quantitative RT-PCR and detection of tumour cell dissemination in breast cancer patients: plasmid versus cell line dilutions.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(8):1241-5.
2003: Hans Wildiers; Gunther Guetens; Gert de Boeck; E Verbeken; Bart Landuyt; Willy Landuyt; Ernst A de Bruijn; Allan T van Oosterom
Effect of antivascular endothelial growth factor treatment on the intratumoral uptake of CPT-11.
British journal of cancer 2003;88(12):1979-86.
2003: Ernest C Borden; Laurence H Baker; Robert S Bell; Vivien Bramwell; George D Demetri; Burton L Eisenberg; Christopher D M Fletcher; Jonathan A Fletcher; Marc Ladanyi; Paul Meltzer; Brian O'Sullivan; David R Parkinson; Peter W T Pisters; Scott Saxman; Samuel Singer; Murali Sundaram; Allan T van Oosterom; Jaap Verweij; Jill Waalen; Sharon W Weiss; Murray F Brennan
Soft tissue sarcomas of adults: state of the translational science.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(6):1941-56.
2003: Ferry A L M Eskens; Herlinde Dumez; Ronald Hoekstra; A Perschl; C Brindley; S Böttcher; Wim Wynendaele; J Drevs; Jaap Verweij; Allan T van Oosterom
Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumours.
European journal of cancer (Oxford, England : 1990) 2003;39(7):917-26.
2003: Hans Wildiers; Martin Highley; Ernst A de Bruijn; Allan T van Oosterom
Pharmacology of anticancer drugs in the elderly population.
Clinical pharmacokinetics 2003;42(14):1213-42.
2002: Gunther Guetens; Gert de Boeck; M Wood; Robert A A Maes; A A M Eggermont; Martin Highley; Allan T van Oosterom; Ernst A de Bruijn; Ubbo R Tjaden
Hyphenated techniques in anticancer drug monitoring. I. Capillary gas chromatography-mass spectrometry.
Journal of chromatography. A 2002;976(1-2):229-38.
2002: Allan T van Oosterom; Ian R Judson; Jaap Verweij; Sigrid Stroobants; Herlinde Dumez; Eugenio Donato di Paola; Raf Sciot; Martine Van Glabbeke; Sasa Dimitrijevic; Ole Steen Nielsen
Update of phase I study of imatinib (STI571) in advanced soft tissue sarcomas and gastrointestinal stromal tumors: a report of the EORTC Soft Tissue and Bone Sarcoma Group.
European journal of cancer (Oxford, England : 1990) 2002;38 Suppl 5():S83-7.
2002: Gunther Guetens; Gert de Boeck; Martin Highley; Allan T van Oosterom; Ernst A de Bruijn
Oxidative DNA damage: biological significance and methods of analysis.
Critical reviews in clinical laboratory sciences 2002;39(4-5):331-457.
2002: Herlinde Dumez; M Louwerens; A Pawinsky; A S T Planting; M J A de Jonge; Allan T van Oosterom; Martin Highley; Gunther Guetens; Marijke Mantel; Gert de Boeck; Ernst A de Bruijn; Jaap Verweij
The impact of drug administration sequence and pharmacokinetic interaction in a phase I study of the combination of docetaxel and gemcitabine in patients with advanced solid tumors.
Anti-cancer drugs 2002;13(6):583-93.
2002: Hans Wildiers; Gunther Guetens; Gert de Boeck; Willy Landuyt; Eric Verbeken; Martin Highley; Ernst A de Bruijn; Allan T van Oosterom
Melphalan availability in hypoxia-inducible factor-1alpha+/+ and factor-1alpha-/- tumors is independent of tumor vessel density and correlates with melphalan erythrocyte transport.
International journal of cancer. Journal international du cancer 2002;99(4):514-9.
2002: Luc Y Dirix; Allan T van Oosterom
Gene-expression profiling to classify soft-tissue sarcomas.
Lancet 2002;359(9314):1263-4.
2002: L Svancárová; Jean-Yves Blay; Ian R Judson; Q G C M van Hoesel; Allan T van Oosterom; Axel Le Cesne; HJ Keizer; C Hermans; Martine Van Glabbeke; Jaap Verweij; Pancras Hogendoorn; Ole Steen Nielsen
Gemcitabine in advanced adult soft-tissue sarcomas. A phase II study of the EORTC Soft Tissue and Bone Sarcoma Group.
European journal of cancer (Oxford, England : 1990) 2002;38(4):556-9.
2002: Ron H J Mathijssen; Alex Sparreboom; Herlinde Dumez; Allan T van Oosterom; Ernst A de Bruijn
Altered irinotecan metabolism in a patient receiving phenytoin.
Anti-cancer drugs 2002;13(2):139-40.
2002: Joris Ceulemans; Ivo De Wever; Raf Sciot; Maria Debiec-Rychter; Allan T van Oosterom
A sarcoma at the site of previous extravasation of adriamycin.
Sarcoma 2002;6(4):135-9.
2001: Harry J M Groen; Elisabeth G E de Vries; Wim Wynendaele; Winette T A van der Graaf; Eelco Fokkema; M J Lechuga; Italo POggesi; L Y Dirix; Allan T van Oosterom
PNU-145156E, a novel angiogenesis inhibitor, in patients with solid tumors: a phase I and pharmacokinetic study.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(12):3928-33.
2001: Allan T van Oosterom; Ian Judson; Jaap Verweij; S Stroobants; Eugenio Donato di Paola; Sasa Dimitrijevic; M Martens; A Webb; Raf Sciot; Martine Van Glabbeke; S Silberman; Ole Steen Nielsen
Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.
Lancet 2001;358(9291):1421-3.
2001: Ian Judson; John A Radford; M Harris; Jean-Yves Blay; Q G C M van Hoesel; Axel Le Cesne; Allan T van Oosterom; M J Clemons; Claus Kamby; C Hermans; J Whittaker; Eugenio Donato di Paola; Jaap Verweij; S Nielsen
Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group.
European journal of cancer (Oxford, England : 1990) 2001;37(7):870-7.
2001: J Aerts; Wim Wynendaele; Robert Paridaens; Marie-Rose Christiaens; Walter Van den Bogaert; Allan T van Oosterom; F Vandekerckhove
A real-time quantitative reverse transcriptase polymerase chain reaction (RT-PCR) to detect breast carcinoma cells in peripheral blood.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2001;12(1):39-46.
2000: Eelco Fokkema; J Verweij; Allan T van Oosterom; D R A Uges; R Spinelli; O Valota; Elisabeth G E de Vries; Harry J M Groen
A prolonged methoxymorpholino doxorubicin (PNU-152243 or MMRDX) infusion schedule in patients with solid tumours: a phase 1 and pharmacokinetic study.
British journal of cancer 2000;82(4):767-71.
1999: A Pawinski; S Tumolo; G Hoesel; A Cervantes; Allan T van Oosterom; G H Boes; S Pecorelli
Cyclophosphamide or ifosfamide in patients with advanced and/or recurrent endometrial carcinoma: a randomized phase II study of the EORTC Gynecological Cancer Cooperative Group.
European journal of obstetrics, gynecology, and reproductive biology 1999;86(2):179-83.
1999: Wim Wynendaele; Rita Derua; M F Hoylaerts; A Pawinski; E Waelkens; E A de Bruijn; Robert Paridaens; Wilfried Merlevede; Allan T van Oosterom
Vascular endothelial growth factor measured in platelet poor plasma allows optimal separation between cancer patients and volunteers: a key to study an angiogenic marker in vivo?
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1999;10(8):965-71.
1999: Allan T van Oosterom
Docetaxel (Taxotere) and gemcitabine phase I and early phase II studies: results to date and an overview of ongoing studies.
Seminars in oncology 1999;26(3 Suppl 10):8-11.
1999: Martine Van Glabbeke; Allan T van Oosterom; J W Oosterhuis; Henning Mouridsen; D Crowther; R Somers; J Verweij; A Santoro; J Buesa; T Tursz
Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens--a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(1):150-7.
1999: A Pawinski; D Crowther; HJ Keizer; Paul A Voûte; R Somers; Martine Van Glabbeke; MA Lentz; Allan T van Oosterom
The EORTC Phase II study of iproplatin in advanced osteogenic sarcoma.
European journal of cancer (Oxford, England : 1990) 1999;35(1):163-4.
1998: Wim Wynendaele; Allan T van Oosterom; A Pawinski; E A de Bruijn; Robert A A Maes
Angiogenesis: possibilities for therapeutic interventions.
Pharmacy world & science : PWS 1998;20(6):225-35.
1998: A Pawinski; G Favalli; E Ploch; T Sahmoud; Allan T van Oosterom; S Pecorelli
PVB chemotherapy in patients with recurrent or advanced dysgerminoma: a Phase II study of the EORTC Gynaecological Cancer Cooperative Group.
Clinical oncology (Royal College of Radiologists (Great Britain)) 1998;10(5):301-5.
1997: A Pawinski; Allan T van Oosterom; Ronald de Wit; S Fosså; J Croles; A Svedberg; MA Lentz; P H M De Mulder
An EORTC phase II study of the efficacy and safety of linomide in the treatment of advanced renal cell carcinoma.
European journal of cancer (Oxford, England : 1990) 1997;33(3):496-9.
1997: Luc Y Dirix; Peter B Vermeulen; A Pawinski; Annemie Prové; Ina H Benoy; C De Pooter; M Martin; Allan T van Oosterom
Elevated levels of the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in sera of cancer patients.
British journal of cancer 1997;76(2):238-43.